Checkpoint kinase 1 (CHK1S345), selectively inhibited by prexasertib (ACR-368), was exclusively quantified by RPPA and has demonstrated early promising results as a therapeutic target in platinum-resistant endometrial cancer (NCT05548296). The gene discussed is CHEK1; the disease is endometrial cancer.